Want to see JP:2160 full AI Analyst Report?
2160 Stock Chart & Stats
¥3370.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥3370.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥2,112.00 - ¥3,740.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)1.07M
Market Cap
¥192.64B
Enterprise Value¥172.97K
Total Cash (Recent Filing)¥17.16B
Total Debt (Recent Filing)¥5.07B
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 16, 2026EPS Estimate
27.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-102.58
Shares Outstanding65,828,230
10 Day Avg. Volume965,260
30 Day Avg. Volume1,072,573
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,800.00Price Target Upside12.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)15.29
Revenue Forecast (FY)¥40.18B
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA gross margin near 75% indicates strong underlying product economics and pricing potential. If sustained, this provides a foundation for restoring operating profitability when revenue growth improves and cost control becomes more effective.
Manageable LeverageLow debt relative to equity and a sizable equity base provide financial flexibility compared with a highly leveraged biotechnology business. This may give GNI more capacity to fund operations and pursue development while limiting immediate balance-sheet pressure.
Revenue Base Remains IntactThe company continues to maintain a revenue-generating commercial base rather than facing an outright top-line contraction. That foundation can support operating leverage and earnings recovery if product adoption and execution improve over the coming periods.
Bears Say
Return To Significant LossesThe return to sizable operating and net losses shows that strong gross margins are not currently converting into sustainable earnings. Continued losses can restrict internal investment capacity and make future performance highly dependent on operational recovery.
Persistent Cash BurnNegative operating and free cash flow indicate weak cash conversion and a reliance on available funding when profitability deteriorates. Even though TTM free cash flow improved from the prior period, ongoing cash burn remains a material execution and financing risk.
Deteriorating Revenue MomentumSlowing revenue momentum reduces the prospect of near-term operating leverage and makes it harder to absorb the company’s cost base. A prolonged deceleration could delay the return to profitability and weaken the sustainability of its commercial trajectory.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥2112.00 and its highest was ¥3740.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥192.64B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Nov 16, 2026 which is in 65 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on Aug 14, 2026. The company reported ¥2.54 earnings per share for the quarter, beating the consensus estimate of -¥61.64 by ¥64.18.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is 27.3.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 65,828,230 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of ¥2.54 in its last earnings report, beating expectations of -¥61.64. Following the earnings report the stock price went up 1.312%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
2160 Stock 12 Month Forecast
Average Price Target
¥3,800.00
▲(12.76% Upside)